Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab tirumotecan plus pucotenlimab in advanced cholangiocarcinoma
ChiCTR2500105431Phase 2Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sacituzumab tirumotecan and pucotenlimab in cholangiocarcinoma (CCA) and gallbladder cancer (2 cohorts), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Objective response rate (ORR). Started Jul 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecanpucotenlimab
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2500105431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105431.